On the risk of delisting of ordinary shares of Eagle Pharmaceuticals, Inc. (EGRX)

The International Trading System Limited (hereinafter — ITS) hereby informs on the delisting risk of ordinary shares of Eagle Pharmaceuticals, Inc. (ISIN US2697961082, hereinafter — Shares, QI) from The Nasdaq Stock Market LLC (hereinafter — Nasdaq).

Information on delisting risk of ordinary shares by Nasdaq 

As previously disclosed, on November 27, 2023, Eagle Pharmaceuticals, Inc. (hereinafter — the Company) received a delinquency notification letter (the “Notice”) from the Listing Qualifications Department of Nasdaq notifying the Company that due to the delay in filing the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, (the “Form 10-Q”), the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”), which required listed companies to timely file all periodic financial reports with the Securities and Exchange Commission (the “SEC”).

On February 13, 2024, the Company submitted Current report on Form 8-K to The United States Securities and Exchange Commission (the “SEC”). According to the report, on February 8, 2024, following timely submission of such plan, Nasdaq notified the Company that it was granted an extension of 180 days from the due date of the Form 10-Q, or until May 13, 2024, to regain compliance with the Rule. The Company may be able to regain compliance with the Rule by filing the Form 10-Q with the SEC (and any other reports required to be filed) on or before the end of such extension period.

If the Company fails to regain compliance prior to the expiration of the extension period, Nasdaq will provide written notification that the Company’s securities will be delisted. For more information, please refer to the report available on the SEC website.

Information regarding possible actions to be taken by ITS Ltd.

ITS Ltd. (hereinafter – ITS) conducts regular monitoring of the relevant information disclosed by the Company. Delisting of the Company’s securities (hereinafter – Qualified Investments) by Nasdaq will be considered to costitute a breach of the ITS Regulations on admitting financial instruments to trading and result in termination of trading in the Qualified Investments on ITS. In case Nasdaq decides to suspend trading in the Company's securities until the date of their delisting on Nasdaq, ITS may make a similar decision.